Parisa Danaietash

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

Parisa Danaietash, Bruno Flamion, Joël Ménard et al. · Hypertension · 2020 · 88 citations · Full text

Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

Liffert Vogt, Carlos Chiurchiu, Harbajan Chadha‐Boreham et al. · Hypertension · 2010 · 47 citations · Full text

Hypertension, Urotensin System, Renal Function +22

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Paul H. Ratner, Charles P. Andrews, Frank C. Hampel et al. · Allergy Asthma and Clinical Immunology · 2017 · 30 citations · Full text

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

Parisa Danaietash, Ji‐Guang Wang, George K. Dresser et al. · Journal of Clinical Hypertension · 2022 · 27 citations · Full text

Blood Pressure Monitoring, Molecular Pharmacology, Hypertension +13